Navigation Links
New therapy based on magnetic stimulation shows promise for non-drug treatment for migraine
Date:4/29/2009

A new UCSF study examining the mechanism of a novel therapy that uses magnetic pulses to treat chronic migraine sufferers showed the treatment to be a promising alternative to medication.

The therapy is called transcranial magnetic stimulation, or TMS. Study findings were presented today (April 29, 2009) during the annual American Academy of Neurology scientific meeting in Seattle.

In a previous randomized controlled clinical study by Ohio State University Medical Center, TMS was used to treat patients who suffer from migraine with aura, a condition in which a variety of mostly visual sensations come before or accompany the pain of a migraine attack. The study showed that TMS treatment was superior to the placebo given to the control group. Patients were pain-free at follow-up intervals of 2, 24 and 48 hours.

In the new study, conducted in rats, UCSF researchers focused on understanding the mechanism of action of TMS therapy -- how the treatment interacted with the brain to produce the pain-free outcomes of patients in the previous study.

The UCSF research identified potential opportunities to enhance treatment strategies in patients. One example, the study team noted, was that factors such as time and peak intensity of stimulation may be important components in the brain's response to TMS.

"The data demonstrate a biological rationale for the use of TMS to treat migraine aura," said Peter Goadsby, MD, PhD, lead investigator of the study, professor and director of the UCSF Headache Center. "We found that cortical spreading depression, known as CSD and the animal correlate of migraine aura, was susceptible to TMS therapy, with the wave of neuronal excitation blocked on over 50 percent of occasions."

The study findings showed that migraine aura responds to magnetic stimulation because TMS therapy blocks the wave of neuronal excitation, which is a biological system through which neurons become stimulated to fire. TMS creates a focused magnetic pulse that passes noninvasively through the skull, inducing an electric current to disrupt the abnormal brain waves believed to be associated with migraine, including CSD. CSD in humans precedes migraine with aura.

The American Academy of Neurology estimates that over 30 million Americans suffer from migraine, a syndrome characterized by recurrent, often excruciating headaches. The National Headache Foundation estimates that migraine causes 157 million lost workdays each year due to pain and associated migraine symptoms, resulting in a $13 billion burden to American employers.

Further research is needed, the UCSF team said, but the findings give neurologists a potential new treatment option for migraine sufferers unable to tolerate medication, which can cause stomach bleeding and other painful side effects.


'/>"/>

Contact: Lauren Hammit
lhammit@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
Source:Eurekalert

Related medicine news :

1. Womens International Pharmacy Offers Free Educational Information About Bioidentical Hormone Replacement Therapy
2. Sublingual immunotherapy for inhalant allergies deserves deeper consideration
3. Gene Therapy Improves Diabetic Neuropathy in Study
4. Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer
5. Potential preventative therapy for Type 1 diabetes
6. For Alzheimers Disease, Surveyed Neurologists Identify a Therapys Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
7. Gene alterations associated with response to anthracycline therapy for breast cancer
8. ALS Therapy Development Institute Delivers Impassioned Testimony to Congressional Subcommittee on Veterans Affairs
9. Prostate cancer therapy increases risk of fractures and cardiovascular-related death
10. MedicareSupplementPlans.com Says News Legislation Could Affect Physical, Speech Therapy Benefits for Medicare Recipients
11. Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... CA (PRWEB) , ... August 22, 2017 , ... ... accessible luxurious collection of unique masks and serums that perfectly fuse the beauty ... care advancements, at the 2017 Indie Beauty Expo on August 23rd & 24th ...
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a ... Migraine Relief with the 2017 Women’s Choice Award. The identification by women of an ... out of 4 migraine sufferers are women. In a survey taken by the Women’s ...
(Date:8/22/2017)... California (PRWEB) , ... August 22, 2017 , ... ... that the key to good health is as simple as eating healthy foods. ... food—whether it be storing fat, making insulin, or breaking apart carbohydrates—depends not only ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... recently spoke at a popular international aesthetics conference for medical professionals about the ... his patients’ health and his growing practice. , Dr. George K. Ibrahim ...
(Date:8/22/2017)... NASHVILLE, Tenn. (PRWEB) , ... August 22, 2017 ... ... Company, is pleased to announce the addition of Zack Tisch as the ... services for the KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients ...
Breaking Medicine News(10 mins):
(Date:8/18/2017)... SEATTLE , Aug. 18, 2017  Nortis today ... provide funding for the third year of a Small ... the National Institute of Neurological Disorders and Stroke (NINDS).?  ... Nortis ... ...
(Date:8/17/2017)... -- MJAC2017 , the premier cannabis event devoted to ... its leading lineup. MJAC2017 is proud ... specializing in the development of pharmaceutical and consumer products, will ... The Green Organic Dutchman are gold sponsors for the event, ... ...
(Date:8/17/2017)... CAESAREA, Israel , August 17, 2017 /PRNewswire/ ... digital health Company with mobile health and big ... securities purchase agreements with domestic and non-U.S. investors ... common stock and shares of the Company,s newly ... private placement offerings. The Company expects to conduct ...
Breaking Medicine Technology: